Investor Overview

Corporate Profile

Investor Highlights

Corporate Profile

Read Now
Corporate Profile

Investor Presentation

Read Now
highlightbg1

Our Pipeline

Learn More
highlightbg2
  • Price
  • Change

  • Copyright West LLC.
    Minimum 15 minutes delayed.
Recent Releases

Recent Releases

July 7, 2019

Priority Review Granted to BeiGene’s Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma

June 28, 2019

BeiGene Granted Approval to Transition from the Biotech Chapter of the Hong Kong Stock Exchange to a General Listing

June 20, 2019

BeiGene Announces Phase 1b Clinical Results of Zanubrutinib in Combination with GAZYVA® (Obinutuzumab) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Follicular Lymphoma at the 15th International Conference on Malignant Lympho

Key Metrics

Key Metrics

  • 2,500

    Employees

  • 800+

    Clinical team

  • 4

    Continents

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

Accept